Beijing Strong Biotechnologies, Inc. Logo

Beijing Strong Biotechnologies, Inc.

300406.SZ

(2.5)
Stock Price

14,60 CNY

14.93% ROA

14.2% ROE

17.96x PER

Market Cap.

9.562.247.500,00 CNY

31.28% DER

1.23% Yield

30.55% NPM

Beijing Strong Biotechnologies, Inc. Stock Analysis

Beijing Strong Biotechnologies, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Beijing Strong Biotechnologies, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 DER

The stock has a minimal amount of debt (33%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 Dividend

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

5 ROE

The stock's ROE falls within an average range (14.1%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

6 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (96) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 PBV

The stock's elevated P/BV ratio (3.17x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

10 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

11 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Beijing Strong Biotechnologies, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Beijing Strong Biotechnologies, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Beijing Strong Biotechnologies, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Beijing Strong Biotechnologies, Inc. Revenue
Year Revenue Growth
2011 275.963.544
2012 380.144.035 27.41%
2013 444.625.403 14.5%
2014 508.274.279 12.52%
2015 566.201.720 10.23%
2016 667.402.749 15.16%
2017 694.277.363 3.87%
2018 774.178.200 10.32%
2019 840.861.681 7.93%
2020 848.118.493 0.86%
2021 1.599.384.352 46.97%
2022 1.510.871.884 -5.86%
2023 1.669.428.901 9.5%
2023 1.741.626.675 4.15%
2024 1.696.871.264 -2.64%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Beijing Strong Biotechnologies, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 11.833.233
2012 19.857.095 40.41%
2013 19.156.126 -3.66%
2014 26.148.544 26.74%
2015 26.605.808 1.72%
2016 42.899.082 37.98%
2017 53.656.329 20.05%
2018 61.037.070 12.09%
2019 70.315.492 13.2%
2020 79.055.482 11.06%
2021 127.008.278 37.76%
2022 137.199.751 7.43%
2023 140.390.130 2.27%
2023 162.898.782 13.82%
2024 159.021.184 -2.44%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Beijing Strong Biotechnologies, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 7.883.695
2012 7.638.967 -3.2%
2013 7.815.555 2.26%
2014 8.928.880 12.47%
2015 8.984.847 0.62%
2016 10.337.074 13.08%
2017 16.249.305 36.38%
2018 14.583.648 -11.42%
2019 15.257.457 4.42%
2020 18.438.383 17.25%
2021 39.440.495 53.25%
2022 31.328.435 -25.89%
2023 269.080.074 88.36%
2023 44.978.428 -498.24%
2024 -45.394.701 199.08%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Beijing Strong Biotechnologies, Inc. EBITDA
Year EBITDA Growth
2011 125.402.964
2012 170.734.508 26.55%
2013 225.603.289 24.32%
2014 261.554.226 13.75%
2015 301.184.992 13.16%
2016 322.484.211 6.6%
2017 345.669.664 6.71%
2018 376.368.933 8.16%
2019 418.052.921 9.97%
2020 215.312.878 -94.16%
2021 637.003.278 66.2%
2022 604.920.193 -5.3%
2023 648.788.436 6.76%
2023 730.738.697 11.21%
2024 728.111.800 -0.36%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Beijing Strong Biotechnologies, Inc. Gross Profit
Year Gross Profit Growth
2011 167.395.636
2012 240.839.916 30.5%
2013 303.414.315 20.62%
2014 362.506.623 16.3%
2015 408.435.135 11.24%
2016 456.875.796 10.6%
2017 500.158.849 8.65%
2018 531.936.307 5.97%
2019 578.301.372 8.02%
2020 521.528.743 -10.89%
2021 1.152.601.079 54.75%
2022 1.126.956.684 -2.28%
2023 1.295.593.770 13.02%
2023 1.300.366.695 0.37%
2024 1.263.095.464 -2.95%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Beijing Strong Biotechnologies, Inc. Net Profit
Year Net Profit Growth
2011 100.782.568
2012 137.009.922 26.44%
2013 180.637.381 24.15%
2014 210.640.919 14.24%
2015 245.043.364 14.04%
2016 271.646.051 9.79%
2017 273.151.407 0.55%
2018 300.665.281 9.15%
2019 331.648.680 9.34%
2020 112.277.109 -195.38%
2021 405.651.172 72.32%
2022 389.097.640 -4.25%
2023 518.996.920 25.03%
2023 523.742.821 0.91%
2024 518.900.628 -0.93%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Beijing Strong Biotechnologies, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 0
2012 0 0%
2013 0 0%
2014 1 100%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 0 0%
2021 1 0%
2022 1 0%
2023 0 0%
2023 1 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Beijing Strong Biotechnologies, Inc. Free Cashflow
Year Free Cashflow Growth
2011 21.765.720
2012 105.047.328 79.28%
2013 137.302.613 23.49%
2014 150.075.877 8.51%
2015 89.506.833 -67.67%
2016 166.582.888 46.27%
2017 182.661.414 8.8%
2018 183.048.891 0.21%
2019 127.190.815 -43.92%
2020 105.813.590 -20.2%
2021 275.895.160 61.65%
2022 299.689.931 7.94%
2023 -32.174.787 1031.44%
2023 437.061.417 107.36%
2024 204.676.833 -113.54%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Beijing Strong Biotechnologies, Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 45.898.334
2012 125.486.142 63.42%
2013 147.193.672 14.75%
2014 156.938.955 6.21%
2015 142.586.445 -10.07%
2016 243.206.450 41.37%
2017 207.907.483 -16.98%
2018 256.147.805 18.83%
2019 188.603.373 -35.81%
2020 123.058.597 -53.26%
2021 341.098.641 63.92%
2022 396.165.883 13.9%
2023 0 0%
2023 585.093.494 100%
2024 213.534.204 -174%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Beijing Strong Biotechnologies, Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 24.132.614
2012 20.438.813 -18.07%
2013 9.891.058 -106.64%
2014 6.863.078 -44.12%
2015 53.079.612 87.07%
2016 76.623.562 30.73%
2017 25.246.068 -203.51%
2018 73.098.913 65.46%
2019 61.412.558 -19.03%
2020 17.245.006 -256.12%
2021 65.203.480 73.55%
2022 96.475.951 32.41%
2023 32.174.787 -199.85%
2023 148.032.077 78.26%
2024 8.857.371 -1571.29%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Beijing Strong Biotechnologies, Inc. Equity
Year Equity Growth
2011 288.658.719
2012 385.668.641 25.15%
2013 476.306.023 19.03%
2014 987.026.942 51.74%
2015 1.175.205.046 16.01%
2016 1.388.025.101 15.33%
2017 1.530.027.909 9.28%
2018 1.702.202.535 10.11%
2019 1.970.946.575 13.64%
2020 3.423.468.907 42.43%
2021 2.913.362.205 -17.51%
2022 3.268.773.689 10.87%
2023 3.721.550.155 12.17%
2023 3.572.209.306 -4.18%
2024 3.849.771.304 7.21%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Beijing Strong Biotechnologies, Inc. Assets
Year Assets Growth
2011 316.695.935
2012 432.482.035 26.77%
2013 520.880.017 16.97%
2014 1.044.471.765 50.13%
2015 1.261.765.209 17.22%
2016 1.471.114.424 14.23%
2017 1.778.676.926 17.29%
2018 1.864.725.364 4.61%
2019 2.154.032.631 13.43%
2020 3.963.667.036 45.66%
2021 4.319.709.471 8.24%
2022 4.612.882.060 6.36%
2023 5.175.748.806 10.88%
2023 4.966.599.489 -4.21%
2024 5.298.676.887 6.27%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Beijing Strong Biotechnologies, Inc. Liabilities
Year Liabilities Growth
2011 28.037.216
2012 46.813.393 40.11%
2013 44.573.994 -5.02%
2014 57.444.822 22.41%
2015 86.560.162 33.64%
2016 83.089.323 -4.18%
2017 248.649.017 66.58%
2018 162.522.829 -52.99%
2019 183.086.056 11.23%
2020 540.198.128 66.11%
2021 1.406.347.264 61.59%
2022 1.344.108.369 -4.63%
2023 1.454.198.649 7.57%
2023 1.394.390.184 -4.29%
2024 1.418.137.530 1.67%

Beijing Strong Biotechnologies, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.96
Net Income per Share
0.91
Price to Earning Ratio
17.96x
Price To Sales Ratio
5.48x
POCF Ratio
14.51
PFCF Ratio
17.72
Price to Book Ratio
2.48
EV to Sales
5.58
EV Over EBITDA
13.86
EV to Operating CashFlow
14.77
EV to FreeCashFlow
18.03
Earnings Yield
0.06
FreeCashFlow Yield
0.06
Market Cap
9,56 Bil.
Enterprise Value
9,73 Bil.
Graham Number
11.55
Graham NetNet
1.25

Income Statement Metrics

Net Income per Share
0.91
Income Quality
1.24
ROE
0.14
Return On Assets
0.1
Return On Capital Employed
0.12
Net Income per EBT
0.86
EBT Per Ebit
0.99
Ebit per Revenue
0.36
Effective Tax Rate
0.14

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.75
Operating Profit Margin
0.36
Pretax Profit Margin
0.36
Net Profit Margin
0.31

Dividends

Dividend Yield
0.01
Dividend Yield %
1.23
Payout Ratio
0.11
Dividend Per Share
0.2

Operating Metrics

Operating Cashflow per Share
1.12
Free CashFlow per Share
0.92
Capex to Operating CashFlow
0.18
Capex to Revenue
0.07
Capex to Depreciation
1.83
Return on Invested Capital
0.11
Return on Tangible Assets
0.15
Days Sales Outstanding
246.9
Days Payables Outstanding
77.21
Days of Inventory on Hand
189.92
Receivables Turnover
1.48
Payables Turnover
4.73
Inventory Turnover
1.92
Capex per Share
0.2

Balance Sheet

Cash per Share
1,97
Book Value per Share
6,59
Tangible Book Value per Share
3.65
Shareholders Equity per Share
6.55
Interest Debt per Share
2.13
Debt to Equity
0.31
Debt to Assets
0.23
Net Debt to EBITDA
0.24
Current Ratio
10.36
Tangible Asset Value
2,15 Bil.
Net Current Asset Value
1,19 Bil.
Invested Capital
4714138618
Working Capital
2,35 Bil.
Intangibles to Total Assets
0.33
Average Receivables
1,20 Bil.
Average Payables
0,10 Bil.
Average Inventory
231164673.5
Debt to Market Cap
0.13

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Beijing Strong Biotechnologies, Inc. Dividends
Year Dividends Growth
2015 1
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Beijing Strong Biotechnologies, Inc. Profile

About Beijing Strong Biotechnologies, Inc.

Beijing Strong Biotechnologies, Inc. provides in-vitro diagnostics products and services in the People's Republic of China and internationally. It offers clinical biochemistry products, such as reagents and automatic biochemistry analyzers; coagulation products, including reagents and automated coagulation analyzers; and serology products comprising blood type test cards and automated blood grouping analyzers. The company was founded in 2001 and is headquartered in Beijing, the People's Republic of China.

CEO
Mr. Xi Liu
Employee
1.094
Address
Kuang Yi Building
Beijing, 100191

Beijing Strong Biotechnologies, Inc. Executives & BODs

Beijing Strong Biotechnologies, Inc. Executives & BODs
# Name Age
1 Mr. Qixin Lin
Deputy General Manager
70
2 Mr. Jian Min Wang
Secretary of the Board of Directors
70
3 Ms. Sheng Dan
Deputy GM & Non-Independent Director
70
4 Mr. Qinghai Yang
Deputy General Manager
70
5 Mr. Wei Liu
Chief Financial Officer & Accounting Supervisor
70
6 Mr. Xi Liu
GM & Non-Independent Director
70

Beijing Strong Biotechnologies, Inc. Competitors